Latest Organofluorides Stories
Primary efficacy endpoints met in all nine new trials of investigational PCSK9 inhibitor TARRYTOWN, N.Y. and PARIS, July 30, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
- Primary efficacy endpoints met in all nine new trials of investigational PCSK9 inhibitor - PARIS and TARRYTOWN, N.Y., July 30, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and
HILDEN, Germany and LONDON, July 28, 2014 /PRNewswire/ -- - Collaboration aims to create and commercialize companion diagnostic using genomic data
The Firm is currently representing clients in Risperdal lawsuits that similarly allege the atypical antipsychotic medication caused gynecomastia, a condition categorized by male breast development.
The Firm is representing numerous clients in Risperdal lawsuits who allegedly developed gynecomastia, or male breast growth, due to their use of the atypical antipsychotic medication.
Additional Independent Review Board Approvals Expected for Phase 2 Trial (Study 202) SAN DIEGO, July 22, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc.
NEW YORK, July 17, 2014 /PRNewswire/ -- Exelixis, Inc. (Nasdaq: EXEL) is a development stage biotech company.
North America is a dominant market for PVDF owing to significant demand from the U.S.
Eighty Percent of Patients Treated with G-202 had No Tumor Growth at Two Months SAN ANTONIO, July 15, 2014 /PRNewswire/ -- GenSpera, Inc.
- Withering but not falling off, as a blossom that persists on a twig after flowering.